Zimmer Biomet (ZBH) Stock Forecast & Price Target

Zimmer Biomet
Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

• Zimmer Biomet Holdings, Inc. recently reported second-quarter earnings that exceeded analyst expectations, posting $2.07 in earnings per share against a consensus estimate of $2.01, while also generating $2.18 billion in revenue, which surpassed the projected $2.13 billion and represented a 4.8% year-over-year increase.
• The company has demonstrated strong institutional interest, with major investors such as BlackRock Inc. and Primecap Management Co. CA establishing new positions worth approximately $1.34 billion and $328.58 million, respectively, during the second quarter, signaling confidence in the stock's long-term potential.
• Zimmer Biomet Holdings, Inc. offers a stable income stream for investors through its quarterly dividend of $0.24 per share, which translates to an annualized yield of approximately 0.96% based on the current stock price of $99.52.
• Recent analyst activity has been positive, with Zacks Research upgrading the stock from a "strong sell" to a "hold" rating and Truist Financial raising its price target to $106.00, reflecting a more optimistic outlook on the company's performance.
• The stock is trading at a P/E ratio of 24.21, which is below the consensus price target of $104.42, suggesting that the current valuation may offer an opportunity for capital appreciation as the company continues to grow its revenue.